Emergent BioSolutions | EBS - Выручка от реализации





Продажи Изменить Дата
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
Akebia Therapeutics USD 57.62M 1.14M 2025-12
ALKERMES USD 496.01M 103.1M 2026-06
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Amarin USD 49.22M 451K 2025-12
ANI Pharmaceuticals USD 266M 28.5M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Coherus Biosciences USD 12.75M 1.18M 2025-12
Emergent BioSolutions USD 276.6M 6.1M 2023-12
Exelixis USD 628.69M 17.89M 2026-06
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Heron Therapeutics USD 40.59M 2.38M 2025-12
Ionis Pharmaceuticals USD 268M 22M 2026-06
Ironwood Pharmaceuticals USD 113.04M 6.53M 2026-06
Lexicon Pharmaceuticals USD 5.49M 8.69M 2025-12
Lonza CHF 3.58B 63M 2025-06
Merck USD 16.6B 310M 2026-06
Moderna USD 100M 289M 2026-06
Myriad Genetics USD 190.7M 9.7M 2026-06
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 959M 148M 2026-06
Pacira USD 192.4M 15.4M 2026-06
Pfizer USD 15.03B 530M 2026-06
PTC Therapeutics USD 361M 88M 2026-06
Sanofi EUR 11.95B 710M 2026-06
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
United Therapeutics USD 783.3M 1.8M 2026-06
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12